


## Original Article

Stability of Symptom Clusters in Patients With  
Gastrointestinal Cancers Receiving Chemotherapy

Claire J. Han, RN, PhD, Kerry Reding, RN, PhD, Bruce A. Cooper, PhD, Steven M. Paul, PhD, Yvette P. Conley, PhD, Marilyn Hammer, RN, PhD, Kord M. Kober, PhD, Jon D. Levine, MD, PhD, and Christine Miaskowski, RN, PhD

*School of Nursing (C.J.H., K.R.), University of Washington, Seattle, Washington; School of Nursing (B.A.C., S.M.P., K.M.K., C.M.), University of California, San Francisco, California; School of Nursing (Y.P.C.), University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Nursing (M.H.), Mount Sinai Medical Center, New York, New York; School of Medicine (J.D.L.), University of California, San Francisco, California, USA*

---

**Abstract**

**Context.** Limited evidence suggests that patients with gastrointestinal (GI) cancers receiving chemotherapy (CTX) experience an average of 13 co-occurring symptoms. An alternative to counting symptoms is to evaluate for symptom clusters.

**Objectives.** In a sample of patients with GI cancers receiving CTX ( $n = 399$ ), we evaluated the occurrence, severity, and distress of 38 symptoms in the week before patients' second or third cycle of CTX (Time 1 [T1]), approximately one week after CTX (Time 2 [T2]), and approximately two weeks after CTX (Time 3 [T3]); evaluated for differences in the number and types of symptom clusters at each of these three assessments using ratings of occurrence, severity, and distress; and evaluated for changes in symptom clusters over time.

**Methods.** Modified version of the Memorial Symptom Assessment Scale collected data on 38 common symptoms. Exploratory factor analyses were used to create the symptom clusters.

**Results.** Five distinct symptom clusters were identified across the three symptom dimensions and the three assessments (i.e., psychological, CTX-related, weight change, GI, and epithelial). Psychological, CTX-related, and weight change clusters were relatively stable across all three symptom dimensions and time. Across all three symptom dimensions, GI cluster was identified only at T1 and epithelial cluster was identified at T2 and T3.

**Conclusion.** The number and types of symptom clusters appear to be relatively stable over time and across the symptom dimensions. Ongoing assessment and management of these clusters is warranted across the entire course of CTX. The underlying mechanism for these clusters warrants investigation. *J Pain Symptom Manage* 2019;58:989–1001. © 2019 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.

**Key Words**

*Symptoms, symptom clusters, gastrointestinal cancer, chemotherapy, occurrence, severity, distress*

---

**Introduction**

In the U.S., gastrointestinal (GI) cancers have the third highest incidence in both men and women and are the second leading cause of cancer deaths.<sup>1</sup> Most patients with GI cancers receive chemotherapy (CTX) as their primary treatment.<sup>2,3</sup> Both the cancer

itself and its treatment lead to multiple co-occurring symptoms<sup>4</sup> and associated decrements in patients' quality of life (QOL).<sup>5</sup>

An alternative to counting the number of co-occurring symptoms is to evaluate for symptom clusters. In a recent review,<sup>5</sup> a determination of the congruence in the number and types of symptom

---

*Address correspondence to:* Christine Miaskowski, RN, PhD, School of Nursing, University of California, 2 Koret Way – N631Y, San Francisco, CA 94143-0610, USA. E-mail: [chris.miaskowski@ucsf.edu](mailto:chris.miaskowski@ucsf.edu)

*Accepted for publication:* July 30, 2019.

clusters using different symptom dimensions (e.g., occurrence, severity, distress) and an evaluation of the stability of symptom clusters over time were identified as high priority areas for research.

Only six cross-sectional studies focused on symptom clusters in patients with GI cancers.<sup>6–11</sup> Two of them evaluated patients with pancreatic cancer,<sup>6,11</sup> two evaluated patients with hepatocellular carcinoma,<sup>7,8</sup> one evaluated patients with esophageal cancer,<sup>9</sup> and one compared symptom clusters in younger versus older survivors with colorectal cancer.<sup>10</sup> Because the instruments used to create the symptom clusters varied, no common symptom cluster was identified across these six studies. By contrast, in our recent cross-sectional study that evaluated symptom clusters in patients with a variety of GI cancers,<sup>12</sup> four symptom clusters were identified (i.e., psychological, CTX-related, GI, and weight change) and the numbers and types of symptom clusters were relatively similar across the three symptom dimensions used to create the symptom clusters (i.e., occurrence, severity, distress).

While no studies that evaluated for changes in symptom clusters in patients with GI cancers were identified, in patients with breast,<sup>13–15</sup> lung,<sup>16,17</sup> and ovarian<sup>18</sup> cancers, symptom clusters appear to remain relatively stable over time. Therefore, in this analysis, that builds on our previous study of patients with GI cancers receiving CTX ( $n = 399$ ),<sup>12</sup> we evaluated the occurrence, severity, and distress of 38 symptoms in the week before patients' second or third cycle of CTX (Time 1 [T1]), approximately one week after CTX (Time 2 [T2]), and approximately two weeks after CTX (Time 3 [T3]); evaluated for differences in the number and types of symptom clusters at each of these assessments using ratings of occurrence, severity, and distress; and evaluated for changes in the symptom clusters over time.

## Methods

### Patients and Settings

This analysis is part of a larger study, which evaluated the symptom experience of oncology outpatients receiving CTX.<sup>19</sup> In brief, patients were  $\geq 18$  years of age; had a diagnosis of breast, lung, GI, or gynecological cancer; had received CTX within the preceding four weeks; were scheduled to receive at least two additional cycles of CTX; were able to read, write, and understand English; and gave written informed consent. Patients were recruited from two Comprehensive Cancer Centers, one Veteran's Affairs hospital, and four community-based oncology programs. For this analysis, from a total sample of 1343 patients, 399 patients with GI cancers (e.g., colon, rectal, esophagus, stomach) were evaluated. Patients were recruited from 2010 to 2015.

### Procedures

Patients were approached in the infusion unit, during their first and second cycle of CTX, to discuss participation in the study. After written informed consent was obtained, patients completed questionnaires in their home a total of 6 times over two cycles of CTX. The symptom assessment data from the first three assessments (i.e., T1 [i.e., recovery from previous cycle], T2 [i.e., acute symptoms], T3 [i.e., potential nadir]) were used in these analyses. Medical records were reviewed for disease and treatment information. The parent study was approved by the Committee on Human Research at the University of California, San Francisco, and by each sites' Institutional Review Board at each of the study sites.

### Instruments

Patients completed a demographic questionnaire, Karnofsky Performance Status scale,<sup>20</sup> and Self-Administered Comorbidity Questionnaire.<sup>21</sup> The total Self-Administered Comorbidity Questionnaire score ranges from 0 to 39.<sup>22,23</sup>

A modified version of the 32-item Memorial Symptom Assessment Scale (MSAS)<sup>24</sup> was used to evaluate 38 symptoms commonly associated with cancer and its treatment. Six additional symptoms were assessed: hot flashes, chest tightness, difficulty breathing, abdominal cramps, increased appetite, and weight gain. Patients were asked to indicate whether they had experienced each symptom in the past week (i.e., symptom occurrence). If they had experienced the symptom, they were asked to rate its severity and distress. Severity was rated using a four-point Likert scale (i.e., 1 = slight, 2 = moderate, 3 = severe, 4 = very severe). Distress was rated using a five-point Likert scale (i.e., 0 = not at all, 1 = a little bit, 2 = somewhat, 3 = quite a bit, 4 = very much). The validity and reliability of the MSAS is well established.<sup>24</sup>

### Data Analyses

Data were analyzed using the Statistical Package for the Social Sciences Version 23,<sup>25</sup> STATA Release 15,<sup>26</sup> and MPlus Version 7.3.<sup>27</sup> Descriptive statistics and frequency distributions were calculated for the demographic and clinical characteristics and for symptom occurrence, severity, and distress ratings.

To identify the symptom clusters, exploratory factor analyses (EFAs) were done for the dichotomous (i.e., occurrence) and ordinal (i.e., severity and distress) items using MPlus.<sup>27</sup> For the EFAs, factors were considered to be adequately defined if at least two items (i.e., symptoms) had loadings of  $\geq 0.40$ .<sup>28</sup> Items that loaded on two factors (i.e., cross-loaded) were retained and used to define both factors (i.e., symptom clusters).<sup>28–30</sup>

To have sufficient variation and covariation to perform the EFAs, only symptoms that were present in >20% and <80% of the patients at T1 were included in these analyses. Based on these criteria, 29 of the 38 MSAS symptoms were used. The nine symptoms excluded were as follows: hot flashes, shortness of breath, mouth sores, chest tightness, difficulty breathing, swelling of arms or legs, difficulty swallowing, problems with urination, and vomiting.

For the EFAs using the dichotomous occurrence items, tetrachoric correlations were used to create the matrix of associations.<sup>27</sup> For the EFAs using the ordinal severity and distress ratings, polychoric correlations were used to create the matrix of associations. The simple structure for the occurrence, severity, and distress EFAs was estimated using the method of unweighted least squares with geomin (i.e., oblique) rotation.<sup>27</sup>

The EFAs for severity were done using severity ratings that included a zero (i.e., 0, 1, 2, 3, 4). If the patient indicated that they did not have the symptom (i.e., occurrence), a severity score of zero was assigned. The EFAs for distress were done using distress ratings that included a 0 (did not have the symptom) and the original ratings shifted from 1 (not at all) to 5 (very much). When the initial EFA analyses were done using severity and distress ratings that did not include zero, the pairwise missingness was over 90% and the estimation failed to converge.

Factor solutions were estimated for two through six factors. After examining all the solutions, the factor solution with the greatest interpretability and clinical meaningfulness was selected, given that it met the criteria set for evaluating simple structure (i.e., size of item loadings, number of items on a factor). Then, each factor solution was examined to determine a clinically appropriate name for the symptom cluster. The name of the symptom cluster was based on the majority of the symptoms in the cluster.

#### *Differences in Number and Types of Symptom Clusters*

To evaluate the agreement among the symptoms within the same cluster using occurrence, severity, and distress ratings, within and across each assessment, we used the criteria proposed by Kirkova and Walsh.<sup>31</sup> These authors suggested that to be in agreement with each other, at least 75% of the symptoms in the clusters should be present including the prominent and most important symptom, namely the symptom with the greatest weight from the factor analyses.

## **Results**

### *Demographic and Clinical Characteristics*

Of the total sample ( $n = 399$ ), 54.9% were male, 63.2% were married or partnered, 68.7% were white, and had a mean age of 57.9 ( $\pm 11.8$ ) years. Patients

had an average of 2.3 ( $\pm 1.3$ ) comorbid condition and a Karnofsky Performance Status score of 80.7 ( $\pm 12.5$ ; [Table 1](#)).<sup>12</sup>

### *Symptom Characteristics*

Mean number of symptoms was 13.0 ( $\pm 7.1$ ) at T1, 12.5 ( $\pm 6.7$ ) at T2, and 11.1 ( $\pm 6.1$ ) at T3 ([Table 1](#)). The occurrence, severity, and distress ratings for each symptom at each assessment are listed in [Table 2](#). As shown in [Appendix Table 1](#), across the three assessments, lack of energy, numbness/tingling in the hands/feet, difficulty sleeping, pain, and feeling drowsy were the five symptoms with the highest occurrence rates. In patients who reported the symptoms, the five most severe symptoms were as follows: problems with sexual interest or activity, change in the way food tastes, lack of energy, difficulty sleeping, and constipation. In terms of symptoms with the highest distress ratings, lack of energy was the only consistent symptom across the three assessments.

### *Symptom Clusters Based on Occurrence Ratings*

For the T1 assessment, four symptom clusters were identified ([Table 3](#), [Appendix Table 2](#)).<sup>12</sup> Factor 1 with eight symptoms was named the psychological cluster. Factor 2 with eight symptoms was named the CTX-related cluster. Factor 3 with three symptoms was named the GI cluster. Factor 4 with two symptoms was named the weight change cluster. For the T2 assessment, four symptom clusters were identified ([Table 3](#), [Appendix Table 3](#)). Factor 1 with eight symptoms was named the psychological cluster. Factor 2 with 12 symptoms was named the CTX-related cluster. Factor 3 with three symptoms was named the weight change cluster. Of note, lack of appetite loaded negatively on the weight change symptom cluster, which indicates that lower scores on this symptom (i.e., increased appetite) were more likely to be present among patients with this symptom cluster. Factor 4 with three symptoms was named the epithelial cluster. For the T3 assessment, four symptom clusters were identified ([Table 3](#), [Appendix Table 4](#)). Factor 1 with eight symptoms was named the psychological cluster. Factor 2 with 10 symptoms was named the CTX-related cluster. Factor 3 with two symptoms was named the weight change cluster. Factor 4 with three symptoms was named the epithelial cluster.

### *Symptom Clusters Based on Symptom Severity*

For the T1 assessment, four symptom clusters were identified ([Table 3](#), [Appendix Table 5](#)).<sup>12</sup> Factor 1 with eight symptoms was named the psychological cluster. Factor 2 with eight symptoms was named the CTX-related cluster. Factor 3 with four symptoms was named the GI cluster. Factor 4 with two symptoms was named the weight change cluster. For the T2

**Table 1**  
**Demographic and Clinical Characteristics of Patients**  
**With Gastrointestinal Cancers (N = 399)**

Characteristic	Mean (SD)
Age (yrs)	57.9 (11.8)
Education (yrs)	16.0 (3.0)
Body mass index (kilograms/metered squared)	25.8 (5.3)
Karnofsky Performance Status score	80.7 (12.5)
Number of comorbidities out of 13	2.3 (1.3)
Self-administered Comorbidity Questionnaire score	5.4 (2.9)
Time since cancer diagnosis (yrs)	1.4 (2.8)
Time since diagnosis (median)	0.4
Number of prior cancer treatments (out of 9)	1.4 (1.3)
Number of metastatic sites including lymph node involvement (out of 9)	1.5 (1.1)
Number of metastatic sites excluding lymph node involvement (out of 8)	0.9 (1.0)
Mean number of MSAS symptoms (out of 38)	
Time 1—before the initiation of the second or third cycle of CTX	13.0 (7.1)
Time 2—approximately one week after CTX	12.5 (6.7)
Time 3—approximately two weeks after CTX	11.1 (6.2)
	<i>n</i> (%)
Gender	
Female	180 (45.1)
Male	219 (54.9)
Ethnicity	
White	274 (68.7)
Black	36 (9.0)
Asian or Pacific Islander	46 (11.5)
Hispanic, mixed, or other	43 (10.8)
Married or partnered (% yes)	252 (63.2)
Lives alone (% yes)	74 (18.5)
Childcare responsibilities (% yes)	81 (20.3)
Care of adult responsibilities (% yes)	27 (6.8)
Currently employed (% yes)	133 (33.3)
Income	
<\$30,000	73 (18.4)
\$30,000 to <\$70,000	69 (17.4)
\$70,000 to <\$100,000	61 (15.3)
>\$100,000	155 (38.8)
Exercise on a regular basis (% yes)	263 (65.9)
Current or history of smoking (% yes)	122 (30.6)
Receiving neoadjuvant chemotherapy (% yes)	34 (8.5)
Type of prior cancer treatment	
No prior treatment	113 (28.3)
Only surgery, CTX, or RT	149 (37.3)
Surgery & CTX, or surgery & RT, or CTX & RT	85 (21.3)
Surgery & CTX & RT	42 (10.5)
Gastrointestinal cancer diagnoses	
Colon	185 (46.4)
Rectal	80 (20.1)
Pancreatic	74 (18.5)
Esophageal	21 (5.3)
Gastric	19 (4.8)
Gallbladder/bile duct	10 (2.5)
Liver	6 (1.5)
Small intestine	6 (1.5)
Anal	5 (1.3)
Other	25 (6.3)

MSAS = Memorial Symptom Assessment Scale; CTX = chemotherapy; RT = radiation therapy.

Reprinted with permission from reference<sup>12</sup>.

assessment, four symptom clusters were identified (Table 3, Appendix Table 6). Factor 1 with seven symptoms was named the psychological cluster. Factor 2 with 13 symptoms was named the CTX-related cluster. Factor 3 with four symptoms was named the weight

change cluster. Weight loss and lack of appetite loaded negatively on the weight change symptom cluster, which indicates that lower scores on this symptom (i.e., increased appetite and weight gain) were more likely to be present among patients with this symptom cluster. Factor 4 with four symptoms was named the epithelial cluster. For the T3 assessment, four symptom clusters were identified (Table 3, Appendix Table 7). Factor 1 with seven symptoms was named the psychological cluster. Factor 2 with 12 symptoms was named the CTX-related cluster. Factor 3 with four symptoms was named the weight change cluster. Factor 4 with three symptoms was named the epithelial cluster.

#### *Symptom Clusters Based on Symptom Distress*

For the T1 assessment, four symptom clusters were identified (Table 3, Appendix Table 8).<sup>12</sup> Factor 1 with 10 symptoms was named the psychological cluster. Factor 2 with eight symptoms was named the CTX-related cluster. Factor 3 with two symptoms was named the weight change cluster. Factor 4 with two symptoms was named the GI cluster. For the T2 assessment, four symptom clusters were identified (Table 3, Appendix Table 9). Factor 1 with eight symptoms was named the psychological cluster. Factor 2 with 10 symptoms was named the CTX-related cluster. Factor 3 with two symptoms was named the weight change cluster. Factor 4 with four symptoms was named the epithelial cluster. For the T3 assessment, four symptom clusters were identified (Table 3, Appendix Table 10). Factor 1 with nine symptoms was named the psychological cluster. Factor 2 with nine symptoms was named the CTX-related cluster. Factor 3 with four symptoms was named the weight change cluster. Factor 4 with three symptoms was named the epithelial cluster.

#### *Similarities and Differences in the Number and Types of Symptom Clusters*

Across all three symptom dimensions and assessments, the number of symptom clusters identified was four. As summarized in Table 4, the psychological, CTX-related, and weight change clusters were found across all three symptom dimensions and time points. The GI cluster was identified across all three dimensions but only at T1. The epithelial cluster was found across all three dimensions but only at T2 and T3.

#### *Agreement in the Types of Symptoms Within Each Symptom Cluster*

The specific symptoms within each cluster were relatively stable over time (Table 4). For the psychological cluster, the total number of symptoms ranged from 7 to 10 and the percent agreement ranged from 50.0% to 71.4%. The six symptoms that were included in all nine EFAs were as follows: lack of

Table 2  
Occurrence Rates and Severity and Distress Ratings for Symptoms Over One Cycle of Chemotherapy

Symptoms <sup>a</sup>	Occurrence Rates % (n)			Severity Ratings With Zeros <sup>b</sup> Mean (SD)			Severity Ratings Without Zeros <sup>c</sup> Mean (SD)			Distress Ratings <sup>d</sup> Mean (SD)		
	Time 1 <sup>e</sup>	Time 2	Time 3	Time 1	Time 2	Time 3	Time 1	Time 2	Time 3	Time 1	Time 2	Time 3
Lack of energy	79.7 (318)	76.2 (304)	67.2 (268)	1.62 (1.0)	1.73 (1.1)	1.48 (1.1)	2.03 (0.7)	2.06 (0.7)	2.05 (0.7)	1.72 (1.1)	1.88 (1.0)	1.71 (1.1)
Numbness/tingling in hands/feet	62.2 (248)	63.4 (253)	54.4 (217)	1.20 (1.1)	1.31 (1.2)	1.11 (1.1)	1.95 (0.8)	1.99 (0.8)	1.90 (0.8)	1.62 (1.1)	1.63 (1.1)	1.47 (1.1)
Difficulty sleeping	60.7 (242)	56.6 (226)	55.1 (220)	1.21 (1.1)	1.17 (1.1)	1.15 (1.1)	1.99 (0.7)	1.98 (0.7)	1.94 (0.7)	1.73 (1.3)	1.70 (1.0)	1.57 (1.0)
Pain	59.4 (237)	52.4 (209)	50.6 (202)	1.12 (1.1)	1.05 (1.1)	1.06 (1.2)	1.90 (0.7)	1.93 (0.7)	1.97 (0.7)	1.72 (1.1)	1.79 (1.0)	1.75 (1.1)
Feeling drowsy	57.1 (228)	56.6 (226)	46.9 (187)	1.01 (1.0)	1.06 (1.0)	0.87 (0.9)	1.78 (0.7)	1.82 (0.6)	1.74 (0.6)	1.14 (1.0)	1.22 (1.0)	1.13 (1.0)
Nausea	50.9 (203)	55.1 (220)	43.1 (172)	0.90 (1.1)	1.05 (1.1)	0.78 (0.9)	1.81 (0.7)	1.84 (0.8)	1.71 (0.7)	1.68 (1.1)	1.70 (1.0)	1.52 (1.0)
Change in the way food tastes	49.9 (199)	47.1 (188)	39.8 (159)	1.05 (1.2)	1.04 (1.2)	0.80 (1.1)	2.10 (0.8)	2.12 (0.8)	1.92 (0.8)	1.61 (1.2)	1.77 (1.2)	1.54 (1.2)
Worrying	47.1 (188)	36.6 (146)	35.1 (140)	0.85 (1.0)	0.69 (0.9)	0.67 (0.9)	1.82 (0.7)	1.81 (0.6)	1.76 (0.7)	1.52 (0.9)	1.63 (1.0)	1.46 (0.9)
Difficulty concentrating	44.6 (178)	43.9 (175)	39.3 (157)	0.69 (0.9)	0.71 (0.8)	0.66 (0.9)	1.56 (0.6)	1.55 (0.6)	1.59 (0.6)	1.49 (1.0)	1.43 (0.9)	1.33 (0.8)
Dry mouth	44.4 (177)	38.1 (152)	31.8 (127)	0.77 (1.0)	0.70 (0.9)	0.57 (0.9)	1.75 (0.7)	1.79 (0.7)	1.71 (0.7)	1.20 (1.2)	1.14 (1.0)	1.14 (1.1)
Lack of appetite	44.1 (176)	46.4 (185)	36.3 (145)	0.88 (0.8)	0.96 (1.1)	0.78 (1.1)	1.98 (0.8)	2.01 (0.7)	2.01 (0.8)	1.42 (1.0)	1.50 (1.1)	1.22 (0.9)
Constipation	43.9 (175)	39.1 (156)	29.3 (117)	0.87 (1.1)	0.80 (1.1)	0.80 (1.1)	1.99 (0.8)	1.96 (0.7)	1.96 (0.8)	1.67 (1.2)	1.66 (1.1)	1.60 (1.1)
Feeling sad	40.9 (163)	33.3 (133)	29.1 (116)	0.69 (0.9)	0.58 (0.8)	0.53 (0.8)	1.69 (0.6)	1.69 (0.6)	1.71 (0.7)	1.37 (1.0)	1.54 (1.0)	1.48 (0.9)
Hair loss	40.4 (161)	39.8 (159)	38.6 (154)	0.77 (1.1)	0.73 (1.0)	0.78 (1.1)	1.95 (0.9)	1.78 (0.8)	1.89 (0.8)	1.58 (1.1)	1.71 (1.2)	1.69 (1.2)
Diarrhea	38.3 (153)	34.6 (138)	36.1 (144)	0.75 (1.1)	0.73 (1.1)	0.73 (1.0)	1.97 (0.8)	2.03 (0.8)	1.90 (0.7)	1.65 (1.1)	1.71 (1.1)	1.57 (1.1)
Feeling irritable	36.3 (145)	33.8 (135)	31.3 (125)	0.57 (0.9)	0.60 (0.9)	0.57 (0.9)	1.60 (0.7)	1.71 (0.6)	1.69 (0.7)	1.33 (1.2)	1.45 (0.9)	1.37 (1.0)
Changes in the skin	32.6 (130)	34.1 (136)	25.8 (103)	0.62 (1.0)	0.68 (1.0)	0.52 (0.9)	1.91 (0.8)	1.90 (0.8)	1.91 (0.8)	1.61 (1.1)	1.60 (1.2)	1.70 (1.2)
Weight loss	30.1 (120)	27.3 (109)	26.3 (105)	0.53 (0.9)	0.47 (0.8)	0.44 (0.8)	1.78 (0.8)	1.67 (0.7)	1.58 (0.7)	1.38 (1.1)	1.40 (1.2)	1.21 (1.1)
Feeling bloated	29.8 (119)	23.8 (95)	22.1 (88)	0.55 (0.9)	0.48 (0.9)	0.45 (0.9)	1.87 (0.8)	1.96 (0.8)	1.93 (0.7)	1.65 (1.3)	1.70 (1.1)	1.60 (1.0)
Abdominal cramps	28.3 (113)	29.1 (116)	23.1 (92)	0.54 (0.9)	0.56 (0.9)	0.46 (0.9)	1.94 (0.8)	1.88 (0.7)	1.92 (0.7)	1.63 (1.0)	1.58 (1.0)	1.62 (1.0)
Feeling nervous	28.3 (113)	22.1 (88)	19.0 (76)	0.46 (0.8)	0.37 (0.7)	0.34 (0.7)	1.64 (0.7)	1.64 (0.6)	1.69 (0.6)	1.40 (0.9)	1.52 (1.0)	1.39 (0.9)
Dizziness	27.8 (111)	26.3 (105)	19.0 (76)	0.43 (0.8)	0.41 (0.7)	0.32 (0.6)	1.55 (0.7)	1.49 (0.7)	1.53 (0.6)	1.28 (1.1)	1.31 (0.9)	1.36 (0.7)
Problems with sexual interest or activity	27.1 (108)	21.8 (87)	20.8 (83)	0.63 (1.2)	0.54 (1.1)	0.56 (1.1)	2.39 (1.0)	2.42 (0.9)	2.49 (0.9)	1.64 (1.1)	2.01 (1.2)	1.96 (1.2)
“I don’t look like myself”	25.6 (102)	23.6 (94)	23.8 (95)	0.48 (0.9)	0.48 (0.9)	0.44 (0.8)	1.92 (0.7)	2.00 (0.9)	1.76 (0.7)	1.77 (1.1)	1.81 (1.2)	1.62 (1.0)
Sweats	24.8 (99)	18.5 (74)	14.1 (56)	0.42 (0.8)	0.32 (0.7)	0.25 (0.7)	1.75 (0.8)	1.66 (0.7)	1.77 (0.8)	1.12 (1.2)	1.23 (1.0)	1.22 (1.2)
Increased appetite	24.6 (98)	17.0 (68)	18.2 (72)	0.42 (0.8)	0.30 (0.6)	0.28 (0.6)	1.76 (0.6)	1.72 (0.5)	1.58 (0.6)	0.75 (1.1)	0.69 (0.9)	0.58 (0.9)
Cough	23.6 (94)	22.1 (88)	18.5 (74)	0.32 (0.6)	0.32 (0.6)	0.31 (0.7)	1.38 (0.5)	1.43 (0.5)	1.60 (0.6)	0.83 (1.0)	1.02 (0.9)	1.18 (1.1)
Weight gain	22.8 (91)	15.8 (63)	14.0 (56)	0.35 (0.7)	0.23 (0.5)	0.22 (0.6)	1.56 (0.6)	1.45 (0.6)	1.59 (0.7)	0.87 (1.3)	0.93 (1.3)	0.94 (1.3)
Itching	21.1 (84)	17.3 (69)	13.5 (54)	0.38 (0.8)	0.31 (0.7)	0.24 (0.6)	1.83 (0.8)	1.75 (0.6)	1.69 (0.5)	1.44 (1.0)	1.49 (1.0)	1.22 (0.9)
Mouth sores	19.0 (76)	20.1 (80)	19.8 (79)	0.32 (0.7)	0.36 (0.7)	0.37 (0.7)	1.74 (0.8)	1.74 (0.7)	1.76 (0.7)	1.41 (1.2)	1.45 (1.0)	1.47 (1.0)
Shortness of breath	18.3 (73)	13.8 (55)	11.3 (45)	0.29 (0.7)	0.23 (0.6)	0.21 (0.6)	1.59 (0.6)	1.59 (0.6)	1.77 (0.7)	1.54 (1.1)	1.44 (0.9)	1.44 (1.0)
Hot flashes	17.8 (71)	14.3 (57)	10.0 (40)	0.32 (0.8)	0.26 (0.7)	0.19 (0.6)	1.82 (0.7)	1.80 (0.8)	1.86 (0.9)	1.23 (1.1)	1.34 (1.3)	1.42 (1.3)
Difficulty swallowing	16.8 (67)	18.5 (74)	11.5 (46)	0.30 (0.7)	0.33 (0.7)	0.22 (0.6)	1.81 (0.8)	1.72 (0.8)	1.76 (0.7)	1.77 (1.2)	1.52 (1.0)	1.49 (1.1)
Vomiting	15.3 (61)	15.0 (60)	9.8 (39)	0.28 (0.7)	0.27 (0.6)	0.18 (0.6)	1.82 (0.9)	1.82 (0.8)	1.74 (0.6)	1.73 (1.1)	1.68 (1.1)	1.55 (1.0)
Difficulty breathing	14.8 (59)	10.8 (43)	8.5 (34)	0.24 (0.6)	0.16 (0.5)	0.12 (0.5)	1.67 (0.7)	1.55 (0.6)	1.68 (0.6)	1.56 (1.2)	1.32 (1.0)	1.55 (1.2)
Problems with urination	14.0 (56)	15.3 (61)	12.3 (49)	0.25 (0.7)	0.27 (0.6)	0.20 (0.5)	1.83 (0.6)	1.71 (0.7)	1.64 (0.6)	1.68 (1.2)	1.56 (1.2)	1.40 (1.0)
Chest tightness	12.8 (51)	9.3 (37)	5.0 (20)	0.17 (0.5)	0.14 (0.5)	0.07 (0.3)	1.39 (0.5)	1.54 (0.7)	1.33 (0.5)	1.33 (1.2)	1.27 (1.0)	1.22 (1.1)
Swelling of arms or legs	8.5 (34)	5.0 (20)	5.8 (23)	0.16 (0.6)	0.10 (0.4)	0.10 (0.4)	1.97 (0.8)	2.11 (0.9)	1.76 (0.7)	1.53 (1.1)	1.56 (1.1)	1.24 (1.0)

Timing of symptom assessments: Time 1 = before the initiation of next cycle of chemotherapy (i.e., recovery from the second or third cycle of chemotherapy), Time 2 = approximately one week after chemotherapy (i.e., acute symptoms), Time 3 = approximately two weeks after chemotherapy (i.e., potential nadir).

<sup>a</sup>Symptoms from the Memorial Symptom Assessment Scale with the addition of the following six symptoms: chest tightness, difficulty breathing, increased appetite, hot flashes, abdominal cramps, weight gain.

<sup>b</sup>Severity ratings with zeros: 0 = did not have the symptoms, 1 = slight, 2 = moderate, 3 = severe, 4 = very severe.

<sup>c</sup>Severity ratings without zeros: 1 = slight, 2 = moderate, 3 = severe, 4 = very severe.

<sup>d</sup>Distress ratings: 0 = not at all, 1 = a little bit, 2 = somewhat, 3 = quite a bit, 4 = very much.

<sup>e</sup>Orientation column in rank order.



Weight change symptom cluster	Nausea	—	0.404	—	—	—	—	—	—	—	—	—	—	
	Diarrhea	—	0.561	—	—	—	—	—	—	—	—	—	—	
	Total number of symptoms in this cluster	3/5	4/5	2/5	0.620	—	—	—	—	—	—	—	—	
	Increased appetite	0.836	0.785	0.779	0.784	0.708	0.726	0.600	0.621	0.652	0.600	0.621	0.652	
	Weight gain	0.962	0.871	0.929	0.808	0.781	0.877	1.020	1.094	0.965	1.020	1.094	0.965	
	Lack of appetite	—	—	—	-0.419	-0.451	—	-0.467	-0.442	-0.467	-0.467	-0.442	-0.467	
	Weight loss	—	—	—	—	-0.430	—	-0.412	-0.411	-0.411	-0.412	-0.411	-0.411	
	Total number of symptoms in this cluster	2/4	2/4	2/4	3/4	4/4	2/4	4/4	4/4	4/4	4/4	4/4	4/4	
	Epithelial symptom cluster	Hair loss	—	—	—	0.420	0.450	0.489	—	—	—	—	—	—
		Change in the way food tastes	—	—	—	0.573	—	—	—	—	—	—	—	—
Changes in the skin		—	—	—	0.610	0.705	0.820	0.666	0.698	0.666	0.666	0.698	0.624	
Itching		—	—	—	—	0.433	0.469	0.622	0.483	0.622	0.622	0.483	0.526	
"I don't look like myself"		—	—	—	—	0.459	0.511	0.513	0.632	0.513	0.632	0.584	0.584	
Total number of symptoms in this cluster		0/5	0/5	0/5	3/5	4/5	4/5	3/5	3/5	3/5	3/5	3/5	3/5	

Timing of symptom assessments: Time 1 = before the initiation of next cycle of chemotherapy (i.e., recovery from the second or third cycle of chemotherapy), Time 2 = approximately one week after chemotherapy (i.e., acute symptoms), Time 3 = approximately two weeks after chemotherapy (i.e., potential nadir).  
 — = Factor loadings for these symptoms were <0.40.  
 \*Extraction method: unweighted least squares. Rotation method: Geomin (oblique) rotation.

energy, difficulty concentrating, feeling nervous, feeling sad, worrying, and feeling irritable. For the CTX-related cluster, the total number of symptoms ranged from 8 to 13 and the percent agreement ranged from 44.4% to 72.2%. The three symptoms that were included in all nine EFAs were as follows: lack of appetite, weight loss, and change in the way food tastes. For the weight change symptom cluster, the total number of symptoms ranged from 2 to 4 and the percent agreement ranged from 50.0% to 100%. The two symptoms that were included in all nine EFAs were as follows: increased appetite and weight gain. For the epithelial symptom cluster, the total number of symptoms ranged from 0 to 4 and the percent agreement ranged from 0.0% to 80.0%. None of the symptoms were found across all nine EFAs. However, changes in the skin were included in the T2 and T3 EFAs for all three symptom dimensions. Itching and "I don't like myself" were included in two of the severity and distress EFAs (i.e., T2 and T3). For the GI symptom cluster, the total number of symptoms ranged from 0 to 4 and the percent agreement ranged from 0.0% to 80.0%. None of the symptoms were found across all nine EFAs. At the T1 assessment, the only symptom that was included across all three symptom dimensions was abdominal cramps.

### Discussion

This study is the first to provide detailed information on the occurrence, severity, and distress of 38 common symptoms over a cycle of CTX and to evaluate for changes in the number and types of symptom clusters using occurrence, severity, and distress ratings in patients with GI cancers. Similar to previous studies that used the MSAS,<sup>15,18</sup> lack of energy, sleep disturbance, and pain were the most common symptoms in our patients. In terms of severity, problems with sexual interest or activity, which was reported by 27.1% of our sample, had the highest severity ratings across all three assessments ranging from 2.39 to 2.49. In addition, at T2 and T3, this symptom had the highest distress ratings. Given the growing evidence on sexual dysfunction in patients with GI cancers,<sup>32–35</sup> clinicians need to assess for this symptom and initiate appropriate referrals.

While across the three symptom dimensions and the three assessments, five distinct symptom clusters were identified, three of them (i.e., psychological, CTX-related, and weight change) were relatively stable across symptom dimensions and across time. The other two clusters (i.e., GI, epithelial) varied by time but not by symptom dimensions. Overall, our findings suggest that the majority of the symptom clusters remain relatively stable over time. The remainder of the discussion describes each of these symptom clusters.

Table 4  
Summary of Symptom Clusters Across Time Using Different Dimensions of the Symptom Experience

Symptom Cluster	Symptoms Within the Cluster	Occurrence			Severity			Distress		
		Time 1	Time 2	Time 3	Time 1	Time 2	Time 3	Time 1	Time 2	Time 3
Psychological symptom cluster	Lack of energy	X	X	X	X	X	X	X	X	X
	Difficulty concentrating	X	X	X	X	X	X	X	X	X
	Feeling nervous	X	X	X	X	X	X	X	X	X
	Feeling drowsy	X			X			X		
	Feeling sad	X	X	X	X	X	X	X	X	X
	Worrying	X	X	X	X	X	X	X	X	X
	Feeling irritable	X	X	X	X	X	X	X	X	X
	Changes in the skin	X								X
	Problems with sexual interest or activity		X	X	X	X			X	X
	"I don't look like myself"		X							
	Difficulty sleeping			X				X	X	
	Constipation						X			X
	Pain							X		
	Sweats							X		
Percent agreement <sup>a</sup> (n = 14)	57.1%	57.1%	57.1%	57.1%	50.0%	50.0%	71.4%	57.1%	64.3%	
Chemotherapy-related symptom cluster	Dry mouth	X	X	X		X	X		X	X
	Nausea	X	X	X		X	X		X	X
	Itching	X			X			X		
	Lack of appetite	X	X	X	X	X	X	X	X	X
	Weight loss	X	X	X	X	X	X	X	X	X
	Change in the way food tastes	X	X	X	X	X	X	X	X	X
	Changes in the skin	X			X			X		
	Dizziness	X			X			X		
	Cough		X	X		X	X		X	X
	Lack of energy		X	X		X	X			
	Abdominal cramps		X	X		X	X		X	X
	Feeling bloated		X			X				
	Diarrhea		X	X		X	X		X	X
	Feeling drowsy		X	X		X	X		X	X
	Numbness/tingling in the hands/feet		X			X	X			
	Hair loss					X		X		
	"I don't look like myself"					X		X		

	Sweats					X			X	
	Percent agreement <sup>a</sup> (n = 18)	44.4%	66.7%	55.6%	44.4%	72.2%	66.7%	44.4%	55.6%	50.0%
Gastrointestinal symptom cluster	Feeling bloated	X	Not identified	Not identified	X	Not identified	Not identified		Not identified	Not identified
	Abdominal cramps	X			X			X		
	Constipation	X								
	Nausea				X					
	Diarrhea				X			X		
	Percent agreement <sup>a</sup> (n = 5)	60.0%	0	0	80.0%	0	0	40.0%	0	0
Weight change symptom cluster	Increased appetite	X	X	X	X	X	X	X	X	X
	Weight gain	X	X	X	X	X	X	X	X	X
	Lack of appetite		X	X		X	X			X
	Weight loss			X		X	X			X
	Percent agreement <sup>a</sup> (n = 4)	50.0%	75.0%	100.0%	50.0%	100.0%	100.0%	50.0%	50.0%	100.0%
Epithelial symptom cluster	Hair loss	Not identified	X		Not identified	X		Not identified	X	
	Change in the way food tastes		X							
	Changes in the skin		X	X		X	X		X	X
	Itching			X		X	X		X	X
	"I don't look like myself"			X		X	X		X	X
	Percent agreement <sup>a</sup> (n = 5)	0	60.0%	60.0%	0	80.0%	60.0%	0	80.0%	60.0%

Timing of symptom assessments: Time 1 = before the initiation of next cycle of chemotherapy (i.e., recovery from the second or third cycle of chemotherapy), Time 2 = approximately one week after chemotherapy (i.e., acute symptoms), Time 3 = approximately two weeks after chemotherapy (i.e., potential nadir).

<sup>a</sup>By way of example, percentage agreement for psychological symptom cluster at Time 1 using the results for the occurrence dimension was calculated as follows: (8 [total number of symptoms of occurrence dimension at Time 1]/14 [total number of possible symptoms in the psychological symptom cluster in all nine exploratory factors analyses across time and across symptom dimensions]) × 100 = 57.1%.

### *Psychological Symptom Cluster*

While the number of symptoms in the psychological cluster ranged from 7 to 10, lack of energy, difficulty concentrating, feeling nervous, feeling sad, worrying, and feeling irritable were included in all nine EFAs. This cluster was identified in only three of the six studies of symptom clusters in patients with GI cancers<sup>8,10,11</sup> and anxiety and depression were the only two consistent symptoms. This inconsistent finding may be related to the lack of psychological symptoms on the instruments used in the previous studies.

However, in numerous studies of patients with breast<sup>13,36,37</sup> lung,<sup>17,38,39</sup> and heterogeneous cancer diagnoses,<sup>8,18,40–44</sup> psychological or mood-related clusters were identified. Similar to our study, feeling nervous, worrying, and feeling sad were common symptoms in the psychological cluster in previous studies that used the MSAS (breast,<sup>13,15,36</sup> lung,<sup>17,39</sup> ovarian,<sup>18,41</sup> heterogeneous cancers<sup>40,42,44</sup>). In addition, feeling irritable was included in this cluster in seven studies.<sup>13,15,17,18,36,39,42</sup> Taken together, these findings suggest the relative importance of assessing for psychological symptoms across cancer diagnoses and initiating appropriate interventions.

Although lack of energy loaded on all nine EFAs in our study, it did not load on the psychological cluster in any of the aforementioned studies.<sup>13,15,17,18,36,39–42,44,45</sup> However, and consistent with previous reports,<sup>17,39</sup> lack of energy cross-loaded on our CTX-related cluster. Given that lack of energy was the most common, severe, and distressing symptom among our patients, as well as its association with anemia, disease-related digestive hemorrhage, and poorer nutritional status in patients with colorectal cancer,<sup>46</sup> this symptom warrants ongoing assessment and appropriate management.

### *CTX-Related Symptom Cluster*

Although not identified in patients with GI cancers,<sup>6–11</sup> the CTX-related cluster was found in previous studies that used the MSAS (i.e., CTX-neuropathy, sickness behaviors, treatment-related, CTX toxicity) in patients with breast,<sup>15</sup> lung,<sup>17,39</sup> and heterogeneous cancer diagnoses.<sup>42</sup> Across these studies,<sup>15,17,39,42</sup> feeling drowsy, pain, dizziness, lack of energy, nausea, and dry mouth were the common symptoms in this cluster. In our study, this cluster included three additional symptoms (i.e., lack of appetite, weight loss, change in the way food tastes) that were present in all nine EFAs. Of note, at the T1 assessment, these three symptoms were reported by 30.1% (weight loss), 44.1% (lack of appetite), and 49.9% (change in the way food tastes) of the patients. The loading of these symptoms on the CTX-related cluster may be partially explained by the fact that patients with GI cancers often receive oxaliplatin, 5-fluorouracil, and/or irinotecan containing regimens<sup>47,48</sup> that are associated with significant GI toxicity.<sup>49</sup>

### *Weight Change Symptom Cluster*

Although none of the previous studies of patients with GI cancers identified a weight change cluster,<sup>6–11</sup> this cluster was identified in a study of patients with breast cancer receiving CTX.<sup>15</sup> In previous studies that used the MSAS,<sup>13,17,18,36,39,41,42,50</sup> weight loss was included in GI or nutritional clusters. In our weight change cluster, that included weight loss, weight gain, and lack of appetite, weight loss negatively loaded in this cluster. However, lack of appetite and weight loss cross-loaded on the CTX-related cluster. Taken together, these findings suggest that interindividual variability exists in appetite changes and weight management in patients with GI cancers undergoing CTX. Given that a 10% loss<sup>51,52</sup> or gain<sup>53</sup> in pretreatment weight is associated with increased mortality in cancer patients, clinicians should monitor for these symptoms and refer patients for nutritional counseling.

### *GI Symptom Cluster*

The GI cluster was identified across all three dimensions but only at T1. Abdominal cramps was the only consistent symptom in this cluster. While three studies of patients with GI cancers<sup>7,8,11</sup> identified this cluster, the specific symptoms in this cluster included diarrhea,<sup>7,11</sup> nausea,<sup>8</sup> abdominal cramps, and feeling bloated.<sup>7</sup> While a GI cluster is one of the most common symptom clusters identified in other cancer diagnoses (e.g., breast,<sup>13,36,37</sup> lung,<sup>44,54</sup> ovarian,<sup>18,41</sup> heterogeneous cancer diagnoses<sup>40,42,50,55</sup>), the specific symptoms within this cluster are extremely variable.

An interesting finding in our analysis is that all the symptoms in the GI cluster (i.e., feeling bloated, abdominal cramps, constipation, nausea, diarrhea) loaded on the CTX-related cluster at T2 and T3. This finding suggests that these symptoms may be more strongly associated with CTX-related adverse effects during the two weeks after the administration of CTX (i.e., more acute symptoms). A similar shift in GI symptoms between clusters was observed in a study of patients with breast cancer.<sup>14</sup> Additional research is warranted to determine why specific symptoms may load on different clusters across the continuum of cancer treatment.

### *Epithelial Symptom Cluster*

The epithelial cluster was found across all three dimensions, but only at T2 and T3. While none of the previous studies of patients with GI cancers identified this specific cluster,<sup>6–11</sup> some individual symptoms were included in other symptom clusters. For example, change in the way food tastes was included in a gustatory<sup>11</sup> and a pain-appetite<sup>7</sup> cluster. Itching was included in an itching-constipation cluster.<sup>7</sup> In two of our previous studies of patients with breast<sup>15</sup> and lung cancer,<sup>17</sup> this symptom cluster was

identified. In other MSAS studies, the common symptoms, namely: "I don't look like myself,"<sup>13,18,36,42,50</sup> hair loss,<sup>13,18,36,42,50</sup> and changes in the skin<sup>13,36,42,50</sup> loaded on a similar symptom cluster (e.g., body image cluster<sup>18</sup>). Changes in body image associated with the adverse effects of CTX are well documented.<sup>56,57</sup> In addition, patients with GI cancers may face specific body image changes associated with various surgical procedures,<sup>58,59</sup> as well as skin toxicities associated with the administration of targeted therapies.<sup>60,61</sup>

Several limitations need to be considered. Because this study evaluated symptom clusters in patients undergoing CTX, these symptom clusters may not generalize to other types of cancer treatments (e.g., radiation, surgery). The heterogeneity in the GI cancer diagnoses and CTX agents administered may influence the composition of the symptom clusters. Given that we assessed for symptom clusters over only one cycle of CTX, the variability in symptom clusters over additional cycles of CTX warrant investigation.

Our study is the first to provide detailed information on the occurrence, severity, and distress of 38 common symptoms and changes in symptom clusters over time in a relatively large sample of patients with GI cancers. Our findings suggest that four clusters (i.e., psychological distress, CTX-related, weight change) were relatively stable across time and symptom dimensions. Although the other two clusters (i.e., GI, and epithelial) were relatively stable across dimensions, they were not present at all three assessments. Additional studies are needed to confirm our findings and evaluate for underlying mechanisms associated with each of these clusters.

### Disclosures and Acknowledgments

The authors have no conflicts of interest to declare.

This study was funded by a grant from the National Cancer Institute (NCI, CA134900). Dr. Miaskowski is an American Cancer Society Clinical Research Professor and is funded by a K05 award from the NCI (CA168960). Dr. Han is funded by an NCI Training Program in Biobehavioral Cancer Prevention and Control (CA092408).

### References

- Nagel GC, Schmidt S, Strauss BM, Katenkamp D. Quality of life in breast cancer patients: a cluster analytic approach. Empirically derived subgroups of the EORTC-QLQ BR 23—a clinically oriented assessment. *Breast Cancer Res Treat* 2001; 68:75–87.
- Tantoy IY, Cataldo JK, Aouizerat BE, Dhruva A, Miaskowski C. A review of the literature on multiple co-occurring symptoms in patients with colorectal cancer who received chemotherapy alone or chemotherapy with targeted therapies. *Cancer Nurs* 2016;39:437–445.
- Glimelius B, Hoffman K, Graf W, et al. Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. *Ann Oncol* 1995;6:267–274.
- Tantoy IY, Dhruva A, Cataldo J, et al. Differences in symptom occurrence, severity, and distress ratings between patients with gastrointestinal cancers who received chemotherapy alone or chemotherapy with targeted therapy. *J Gastroint Oncol* 2017;8:109–126.
- Miaskowski C, Barsevick A, Berger A, et al. Advancing symptom science through symptom cluster research: expert panel proceedings and recommendations. *J Natl Cancer Inst* 2017;109.
- Reyes-Gibby CC, Chan W, Abbruzzese JL, et al. Patterns of self-reported symptoms in pancreatic cancer patients receiving chemoradiation. *J Pain Symptom Manage* 2007; 34:244–252.
- Ryu E, Kim K, Cho MS, et al. Symptom clusters and quality of life in Korean patients with hepatocellular carcinoma. *Cancer Nurs* 2010;33:3–10.
- Wang Y, O'Connor M, Xu Y, Liu X. Symptom clusters in Chinese patients with primary liver cancer. *Oncol Nurs Forum* 2012;39:E468–E479.
- Wikman A, Johar A, Lagergren P. Presence of symptom clusters in surgically treated patients with esophageal cancer: implications for survival. *Cancer* 2014;120:286–293.
- Agasi-Idenburg SC, Thong MS, Punt CJ, Stuijver MM, Aaronson NK. Comparison of symptom clusters associated with fatigue in older and younger survivors of colorectal cancer. *Support Care Cancer* 2017;25:625–632.
- Burrell SA, Yeo TP, Smeltzer SC, et al. Symptom clusters in patients with pancreatic cancer undergoing surgical resection: Part I. *Oncol Nurs Forum* 2018;45:E36–E52.
- Han CJ, Reding K, Cooper BA, et al. Symptom clusters in patients with gastrointestinal cancers using different dimensions of the symptom experience. *J Pain Symptom Manage* 2019;58:224–234.
- Phligbua W, Pongthavornkamol K, Knobf T, et al. Symptom clusters and quality of life in women with breast cancer receiving adjuvant chemotherapy. *Pac Rim Int J Nurs Res* 2013;17:249–267.
- Albusoul RM, Berger AM, Gay CL, Janson SL, Lee KA. Symptom clusters change over time in women receiving adjuvant chemotherapy for breast cancer. *J Pain Symptom Manage* 2017;53:880–886.
- Sullivan CW, Leutwyler H, Dunn LB, et al. Stability of symptom clusters in patients with breast cancer receiving chemotherapy. *J Pain Symptom Manage* 2018;55:39–55.
- Gift AG, Stommel M, Jablonski A, Given W. A cluster of symptoms over time in patients with lung cancer. *Nurs Res* 2003;52:393–400.
- Russell J, Wong ML, Mackin L, et al. Stability of symptom clusters in patients with lung cancer receiving chemotherapy. *J Pain Symptom Manage* 2019;57:909–922.
- Huang J, Gu L, Zhang L, et al. Symptom clusters in ovarian cancer patients with chemotherapy after surgery: a longitudinal survey. *Cancer Nurs* 2016;39:106–116.
- Sullivan CW, Leutwyler H, Dunn LB, et al. Differences in symptom clusters identified using symptom occurrence rates

- versus severity ratings in patients with breast cancer undergoing chemotherapy. *Eur J Oncol Nurs* 2017;28:122–132.
20. Karnofsky D. Performance scale. Factors that influence the therapeutic response in cancer: A comprehensive treatise 1977: Plenum Press, New York.
21. Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN. The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. *Arthritis Rheum* 2003;49:156–163.
22. Brunner F, Bachmann LM, Weber U, et al. Complex regional pain syndrome 1—the Swiss cohort study. *BMC Musculoskelet Disord* 2008;9:92.
23. Cieza A, Geyh S, Chatterji S, et al. Identification of candidate categories of the International Classification of Functioning Disability and Health (ICF) for a generic ICF Core set based on regression modelling. *BMC Med Res Methodol* 2006;6:36.
24. Portenoy RK, Thaler HT, Kornblith AB, et al. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. *Eur J Cancer* 1994;30:1326–1336.
25. SPSS. IBM SPSS for Windows (Version 23). Armonk, NY: SPSS, Inc., 2015.
26. StataCorp. Stata Statistical Software: Release 15. College Station, Texas: Stata Corporation, 2017.
27. Muthén L, Muthén B. Mplus. The comprehensive modelling program for applied researchers: user's guide. Los Angeles, CA: Muthen and Muthen, 2015;5.
28. Brown T. The common factor model and exploratory factor analysis. *Confirmatory Factor Analysis for Applied Research*. New York: The Guilford Press, 2015.
29. Miaskowski C, Aouizerat BE. Is there a biological basis for the clustering of symptoms? *Semin Oncol Nurs* 2007;23:99–105.
30. Miaskowski C, Aouizerat BE, Dodd M, Cooper B. Conceptual issues in symptom clusters research and their implications for quality-of-life assessment in patients with cancer. *J Natl Cancer Inst* 2007;37:39–46.
31. Kirkova J, Walsh D. Cancer symptom clusters—a dynamic construct. *Support Care Cancer* 2007;15:1011–1036.
32. Canty J, Stabile C, Milli L, et al. Sexual function in women with colorectal/anal cancer. *Sex Med Rev* 2019;7:202–222.
33. Celentano V, Cohen R, Warusavitarne J, Faiz O, Chand M. Sexual dysfunction following rectal cancer surgery. *Int J Colorectal Dis* 2017;32:1523–1530.
34. Frick MA, Vachani CC, Hampshire MK, et al. Survivorship after lower gastrointestinal cancer: patient-reported outcomes and planning for care. *Cancer* 2017;123:1860–1868.
35. Reese JB, Handorf E, Haythornthwaite JA. Sexual quality of life, body image distress, and psychosocial outcomes in colorectal cancer: a longitudinal study. *Support Care Cancer* 2018;26:3431–3440.
36. Suwisith N, Hanucharumkul S, Dodd M, et al. Symptom clusters and functional status of women with breast cancer. *Thai J Nurs* 2008;12:153–165.
37. Kim H-J, Barsevick AM, Tulman L, McDermott PA. Treatment-related symptom clusters in breast cancer: a secondary analysis. *J Pain Symptom Manage* 2008;36:468–479.
38. Lo C, Zimmermann C, Rydall A, et al. Longitudinal study of depressive symptoms in patients with metastatic gastrointestinal and lung cancer. *J Clin Oncol* 2010;28:3084–3089.
39. Wong ML, Cooper BA, Paul SM, et al. Differences in symptom clusters identified using ratings of symptom occurrence vs. severity in lung cancer patients receiving chemotherapy. *J Pain Symptom Manage* 2017;54:194–203.
40. Chen ML, Tseng HC. Symptom clusters in cancer patients. *Support Care Cancer* 2006;14:825–830.
41. Hwang K-H, Cho O-H, Yoo Y-S. Symptom clusters of ovarian cancer patients undergoing chemotherapy, and their emotional status and quality of life. *Eur J Oncol Nurs* 2016;21:215–222.
42. Yates P, Miaskowski C, Cataldo JK, et al. Differences in composition of symptom clusters between older and younger oncology patients. *J Pain Symptom Manage* 2015;49:1025–1034.
43. Thomas BC, Waller A, Malhi RL, et al. A longitudinal analysis of symptom clusters in cancer patients and their sociodemographic predictors. *J Pain Symptom Manage* 2014;47:566–578.
44. Wang D, Fu J. Symptom clusters and quality of life in China patients with lung cancer undergoing chemotherapy. *Afr Health Sci* 2014;14:49–55.
45. O'Sullivan CC, Van Houten HK, Sangaralingham LR, et al. Ten-year trends in antiemetic prescribing in patients receiving highly emetogenic chemotherapy. *J Natl Compr Canc Netw* 2018;16:294–299.
46. Thong MS, Mols F, Wang XS, et al. Quantifying fatigue in (long-term) colorectal cancer survivors: a study from the population-based patient reported outcomes following initial treatment and long term evaluation of survivorship registry. *Eur J Cancer* 2013;49:1957–1966.
47. Saletti P, Zaniboni A. Second-line therapy in advanced upper gastrointestinal cancers: current status and new prospects. *J Gastrointest Oncol* 2018;9:377–389.
48. Ng RCH, Fitzharris BM, Hider PN, Jeffery M. Chemotherapy with platinum compounds for metastatic colorectal cancer. *Cochrane Database Syst Rev*, 2003. <https://doi.org/10.1002/14651858.CD004113>.
49. Lee CS, Ryan EJ, Doherty GA. Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation. *World J Gastroenterol* 2014;20:3751–3761.
50. Molassiotis A, Wengstrom Y, Kearney N. Symptom cluster patterns during the first year after diagnosis with cancer. *J Pain Symptom Manage* 2010;39:847–858.
51. Meyerhardt JA, Kroenke CH, Prado CM, et al. Association of weight change after colorectal cancer diagnosis and outcomes in the Kaiser Permanente Northern California Population. *Cancer Epidemiol Biomarkers Prev* 2017;26:30–37.
52. Yoon SL, Kim JA, Kelly DL, Lyon D, George TJ Jr. Predicting unintentional weight loss in patients with gastrointestinal cancer. *J Cachexia Sarcopenia Muscle* 2019;10:526–535.

53. O'Donoghue N, Shrotriya S, Aktas A, et al. Clinical significance of weight changes at diagnosis in solid tumours. *Support Care Cancer* 2019;27:2725–2733.
54. Wang S-Y, Tsai C-M, Chen B-C, Lin C-H, Lin C-C. Symptom clusters and relationships to symptom interference with daily life in Taiwanese lung cancer patients. *J Pain Symptom Manage* 2008;35:258–266.
55. Skerman HM, Yates PM, Battistutta D. Cancer-related symptom clusters for symptom management in outpatients after commencing adjuvant chemotherapy, at 6 months, and 12 months. *Support Care Cancer* 2012;20:95–105.
56. Dua P, Heiland MF, Kracen AC, Deshields TL. Cancer-related hair loss: a selective review of the alopecia research literature. *Psychooncology* 2017;26:438–443.
57. Park KB, Lee SS, Kwon OK, Chung HY, Yu W. Chronological changes in quality of life after distal gastrectomy for gastric cancer. *J Gastric Cancer* 2017;17:110–119.
58. Trinquinato I, Marques da Silva R, Ticona Benavente SB, Antonietti CC, Siqueira Costa Calache AL. Gender differences in the perception of quality of life of patients with colorectal cancer. *Invest Educ Enferm* 2017;35:320–329.
59. Fingeret MC, Teo I, Epner DE. Managing body image difficulties of adult cancer patients: lessons from available research. *Cancer* 2014;120:633–641.
60. Lacouture ME, Anadkat M, Jatoi A, et al. Dermatologic toxicity occurring during anti-EGFR monoclonal inhibitor therapy in patients with metastatic colorectal cancer: a systematic review. *Clin Colorectal Cancer* 2018;17:85–96.
61. Peng Y, Li Q, Zhang J, et al. Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors. *Biosci Trends* 2019;12:537–552.

## Appendix

*Appendix Table 1*  
**Rank Order of Symptom Occurrence, Severity, and Distress Ratings Over One Cycle of Chemotherapy**

Rank	T1		T2		T3	
	Symptom	%	Symptom	%	Symptom	%
<b>Occurrence Rates</b>						
1	Lack of energy	79.1	Lack of energy	76.2	Lack of energy	67.2
2	Numbness/tingling in the hands/feet	62.2	Numbness/tingling in the hands/feet	63.4	Difficulty sleeping	55.1
3	Difficulty sleeping	60.7	Difficulty sleeping	56.6	Numbness/tingling in hands/feet	54.4
4	Pain	59.4	Feeling drowsy	56.6	Pain	50.6
5	Feeling drowsy	57.1	Nausea	55.1	Feeling drowsy	46.9
6	Nausea	50.9	Pain	52.4	Nausea	43.1
7	Change in the way food tastes	49.9	Change in the way food tastes	47.1	Change in the way food tastes	39.8
8	Worrying	47.1	Lack of appetite	46.4	Difficulty concentrating	39.3
9	Difficulty concentrating	44.6	Difficulty concentrating	43.9	Lack of appetite	36.3
10	Dry mouth	44.4	Hair loss	39.8	Worrying	35.1
Rank	Symptom	Mean (SD)	Symptom	Mean (SD)	Symptom	Mean (SD)
<b>Severity ratings<sup>a</sup></b>						
1	Problems with sexual interest or activity	2.39 (1.0)	Problems with sexual interest or activity	2.42 (0.9)	Problems with sexual interest or activity	2.49 (0.9)
2	Change in the way food tastes	2.10 (0.8)	Change in the way food tastes	2.12 (0.8)	Lack of energy	2.05 (0.7)
3	Lack of energy	2.03 (0.7)	Swelling of arms or legs	2.11 (0.9)	Lack of appetite	2.01 (0.8)
4	Difficulty sleeping	1.99 (0.7)	Lack of energy	2.06 (0.7)	Pain	1.97 (0.7)
5	Constipation	1.99 (0.8)	Diarrhea	2.03 (0.8)	Constipation	1.96 (0.8)
6	Lack of appetite	1.98 (0.8)	Lack of appetite	2.01 (0.7)	Difficulty sleeping	1.94 (0.7)
7	Diarrhea	1.97 (0.8)	Numbness/tingling in the hands/feet	1.99 (0.8)	Feeling bloated	1.93 (0.7)
8	Swelling of arms or legs	1.97 (0.8)	Difficulty sleeping	1.98 (0.7)	Change in the way food tastes	1.92 (0.8)
9	Numbness/tingling in hands/feet	1.95 (0.8)	Constipation	1.96 (0.7)	Abdominal cramps	1.92 (0.7)
10	Hair loss	1.95 (0.9)	Feeling bloated	1.96 (0.8)	Changes in skin	1.91 (0.8)
<b>Distress ratings<sup>b</sup></b>						
1	"I don't look like myself"	1.77 (1.1)	Problems with sexual interest or activity	2.01 (1.2)	Problems with sexual interest or activity	1.96 (1.2)
2	Difficulty swallowing	1.77 (1.2)	Lack of energy	1.88 (1.0)	Pain	1.75 (1.1)
3	Difficulty sleeping	1.73 (1.3)	"I don't look like myself"	1.81 (1.2)	Lack of energy	1.71 (1.1)
4	Vomiting	1.73 (1.1)	Pain	1.79 (1.0)	Changes in skin	1.70 (1.2)
5	Lack of energy	1.72 (1.1)	Change in the way food tastes	1.77 (1.2)	Hair loss	1.69 (1.2)
6	Pain	1.72 (1.1)	Hair loss	1.71 (1.2)	Abdominal cramps	1.62 (1.0)
7	Nausea	1.68 (1.1)	Diarrhea	1.71 (1.1)	Constipation	1.60 (1.1)
8	Problems with urination	1.68 (1.2)	Difficulty sleeping	1.70 (1.0)	Feeling bloated	1.60 (1.0)
9	Constipation	1.67 (1.2)	Feeling bloated	1.70 (1.1)	Difficulty sleeping	1.57 (1.0)
10	Diarrhea	1.65 (1.1)	Vomiting	1.68 (1.1)	Diarrhea	1.57 (1.1)
	Feeling bloated	1.65 (1.3)				

Timing of symptom assessments: Time 1 = before the initiation of next cycle of chemotherapy (i.e., recovery from the second or third cycle of chemotherapy), Time 2 = approximately one week after chemotherapy (i.e., acute symptoms), Time 3 = approximately two weeks after chemotherapy (i.e., potential nadir).

<sup>a</sup>Severity ratings without zeros: 1 = slight, 2 = moderate, 3 = severe, 4 = very severe.

<sup>b</sup>Distress ratings: 0 = not at all, 1 = a little bit, 2 = somewhat, 3 = quite a bit, 4 = very much.

Appendix Table 2  
Exploratory Factor Analysis Using Ratings of Symptom Occurrence Before the Initiation of Next Dose of Chemotherapy (Time 1)<sup>a</sup>

Symptoms	Factor 1	Factor 2	Factor 3	Factor 4
	Psychological Symptom Cluster	Chemotherapy-Related Symptom Cluster	Gastrointestinal Symptom Cluster	Weight Change Symptom Cluster
Lack of energy	<b>0.463</b>	0.307	0.135	-0.128
Difficulty concentrating	<b>0.712</b>	0.057	0.023	-0.079
Feeling nervous	<b>0.822</b>	0.030	-0.113	-0.011
Feeling drowsy	<b>0.404</b>	0.365	-0.014	-0.036
Feeling sad	<b>0.863</b>	-0.039	-0.017	-0.016
Worrying	<b>0.895</b>	-0.213	0.115	-0.001
Feeling irritable	<b>0.642</b>	0.080	0.095	0.025
Dry mouth	0.084	<b>0.451</b>	-0.039	0.121
Nausea	0.025	<b>0.464</b>	0.330	-0.056
Itching	0.048	<b>0.489</b>	-0.174	0.337
Lack of appetite	-0.162	<b>0.844</b>	0.083	-0.147
Weight loss	-0.022	<b>0.617</b>	0.059	-0.220
Change in the way food tastes	0.035	<b>0.466</b>	0.035	0.158
Changes in the skin	<b>0.420</b>	<b>0.500</b>	-0.232	0.047
Dizziness	0.073	<b>0.504</b>	0.094	0.121
Feeling bloated	0.072	0.083	<b>0.689</b>	0.126
Abdominal cramps	0.052	-0.001	<b>0.734</b>	0.159
Constipation	0.011	0.302	<b>0.431</b>	-0.116
Increased appetite	-0.061	0.047	0.094	<b>0.836</b>
Weight gain	-0.005	-0.139	0.024	<b>0.962</b>
Pain	0.310	-0.034	0.268	0.061
Cough	0.231	0.268	-0.138	0.141
Numbness/tingling in the hands/ feet	0.147	0.185	0.086	0.020
Difficulty sleeping	0.254	0.265	0.109	0.084
Diarrhea	0.006	0.207	0.341	0.145
Sweats	0.333	0.051	0.169	0.187
Problems with sexual interest or activity	0.341	0.177	0.065	0.077
Hair loss	0.105	0.320	0.000	0.190
"I don't look like myself"	0.241	0.272	-0.007	0.121

<sup>a</sup>Extraction method: unweighted least squares. Rotation method: Geomin (oblique) rotation. Bold fonts indicate factor loading for symptom was >0.40.

Appendix Table 3  
 Exploratory Factor Analysis Using Ratings of Symptom Occurrence Approximately One Week After Chemotherapy Administration (Time 2)<sup>a</sup>

Symptoms	Factor 1	Factor 2	Factor 3	Factor 4
	Psychological Symptom Cluster	Chemotherapy-Related Symptom Cluster	Weight Change Symptom Cluster	Epithelial Symptom Cluster
Lack of energy	<b>0.414</b>	<b>0.486</b>	-0.164	-0.012
Cough	-0.007	<b>0.501</b>	0.114	-0.027
Dry mouth	-0.105	<b>0.641</b>	0.059	0.095
Nausea	0.002	<b>0.702</b>	-0.040	-0.083
Abdominal cramps	0.095	<b>0.530</b>	0.132	-0.114
Lack of appetite	0.058	<b>0.688</b>	<b>-0.419</b>	0.110
Weight loss	-0.006	<b>0.453</b>	-0.330	0.132
Feeling bloated	0.188	<b>0.478</b>	0.092	-0.091
Diarrhea	-0.003	<b>0.476</b>	-0.136	-0.106
Feeling drowsy	0.283	<b>0.447</b>	0.012	0.003
Numbness/tingling in the hands/feet	-0.060	<b>0.489</b>	0.041	0.017
Difficulty concentrating	<b>0.653</b>	0.175	-0.023	0.068
Feeling nervous	<b>0.656</b>	0.120	0.007	0.042
Feeling sad	<b>0.814</b>	-0.006	-0.072	0.061
Worrying	<b>0.926</b>	0.079	0.000	-0.077
Feeling irritable	<b>0.654</b>	0.061	-0.088	0.114
Problems with sexual interest or activity	<b>0.510</b>	0.030	0.100	-0.153
"I don't look like myself"	<b>0.403</b>	0.026	-0.001	0.347
Increased appetite	-0.026	0.228	<b>0.784</b>	0.065
Weight gain	0.107	-0.033	<b>0.808</b>	0.024
Hair loss	0.282	0.034	0.153	<b>0.420</b>
Change in the way food tastes	-0.029	<b>0.439</b>	-0.141	<b>0.573</b>
Changes in the skin	0.312	-0.087	0.034	<b>0.610</b>
Itching	0.172	0.145	0.203	0.339
Constipation	0.122	0.384	-0.035	-0.030
Pain	0.390	0.273	0.030	-0.317
Difficulty sleeping	0.308	0.329	0.099	-0.055
Sweats	0.249	0.324	0.169	-0.021
Dizziness	0.200	0.338	0.079	0.195

<sup>a</sup>Extraction method: unweighted least squares. Rotation method: Geomin (oblique) rotation. Bold fonts indicate factor loading for symptom was >0.40.

Appendix Table 4  
Exploratory Factor Analysis Using Ratings of Symptom Occurrence Approximately Two Weeks After Chemotherapy Administration (Time 3)<sup>a</sup>

Symptoms	Factor 1	Factor 2	Factor 3	Factor 4
	Psychological Symptom Cluster	Chemotherapy-Related Symptom Cluster	Weight Change Symptom Cluster	Epithelial Symptom Cluster
Lack of energy	<b>0.544</b>	<b>0.462</b>	0.018	-0.044
Difficulty concentrating	<b>0.510</b>	0.255	-0.006	0.025
Feeling nervous	<b>0.787</b>	-0.012	0.009	0.007
Difficulty sleeping	<b>0.421</b>	0.272	0.129	0.054
Feeling sad	<b>0.943</b>	-0.174	-0.023	0.131
Worrying	<b>0.951</b>	-0.040	-0.011	-0.119
Feeling irritable	<b>0.585</b>	0.050	-0.127	0.277
Problems with sexual interest or activity	<b>0.463</b>	0.043	-0.095	0.136
Cough	-0.072	<b>0.545</b>	-0.013	0.026
Dry mouth	0.196	<b>0.535</b>	0.029	0.011
Nausea	0.184	<b>0.560</b>	-0.042	-0.079
Abdominal cramps	0.206	<b>0.478</b>	-0.049	-0.035
Weight loss	-0.092	<b>0.618</b>	-0.412	0.159
Lack of appetite	0.034	<b>0.690</b>	-0.467	0.029
Change in the way food tastes	-0.081	<b>0.505</b>	0.048	0.201
Diarrhea	0.034	<b>0.497</b>	-0.244	-0.043
Feeling drowsy	0.196	<b>0.535</b>	0.029	0.011
Increased appetite	-0.068	0.174	<b>0.600</b>	0.113
Weight gain	0.001	-0.024	<b>1.020</b>	0.038
"I don't look like myself"	0.303	0.081	0.151	<b>0.513</b>
Changes in the skin	0.278	-0.016	-0.059	<b>0.666</b>
Itching	-0.020	-0.036	0.106	<b>0.622</b>
Feeling bloated	0.388	0.315	0.138	-0.223
Numbness/tingling in the hands/feet	0.093	0.324	0.136	-0.051
Pain	0.315	0.251	0.162	-0.097
Hair loss	0.115	0.246	0.098	0.315
Constipation	0.347	0.295	-0.006	0.033
Sweats	0.396	0.088	0.253	0.022
Dizziness	0.194	0.354	0.133	0.203

<sup>a</sup>Extraction method: unweighted least squares. Rotation method: Geomin (oblique) rotation. Bold fonts indicate factor loading for symptom was >0.40.

Appendix Table 5  
Exploratory Factory Analysis Using Ratings of Symptom Severity Before the Initiation of Next Dose of Chemotherapy (Time 1)<sup>a</sup>

Symptoms	Factor 1	Factor 2	Factor 3	Factor 4
	Psychological Symptom Cluster	Chemotherapy-Related Symptom Cluster	Gastrointestinal Symptom Cluster	Weight Change Symptom Cluster
Lack of energy	<b>0.498</b>	0.218	0.151	-0.248
Difficulty concentrating	<b>0.716</b>	0.052	0.009	-0.107
Feeling nervous	<b>0.775</b>	-0.062	0.006	0.045
Feeling drowsy	<b>0.458</b>	0.271	0.033	-0.124
Feeling sad	<b>0.845</b>	-0.064	-0.057	0.030
Worrying	<b>0.800</b>	-0.105	0.063	0.025
Feeling irritable	<b>0.528</b>	0.094	0.175	0.040
Problems with sexual interest or activity	<b>0.428</b>	0.149	-0.006	-0.044
Dizziness	0.051	<b>0.507</b>	0.137	0.035
Weight loss	-0.019	<b>0.582</b>	0.027	-0.278
Lack of appetite	-0.073	<b>0.768</b>	0.079	-0.260
Itching	0.061	<b>0.466</b>	-0.033	0.295
Hair loss	-0.039	<b>0.443</b>	0.026	0.177
Change in the way food tastes	0.029	<b>0.606</b>	0.029	0.100
"I don't look like myself"	0.241	<b>0.418</b>	-0.122	0.089
Changes in the skin	0.347	<b>0.586</b>	-0.249	0.006
Nausea	0.104	0.305	<b>0.404</b>	-0.140
Feeling bloated	0.034	0.102	<b>0.616</b>	0.154
Diarrhea	0.018	0.035	<b>0.561</b>	0.065
Abdominal cramps	0.035	-0.072	<b>0.858</b>	0.004
Constipation	0.108	0.321	0.200	-0.164
Increased appetite	-0.038	0.022	0.297	<b>0.785</b>
Weight gain	0.050	-0.003	0.101	<b>0.871</b>
Cough	0.185	0.295	-0.098	0.119
Dry mouth	0.157	0.269	0.192	0.049
Difficulty sleeping	0.361	0.195	0.081	0.081
Numbness/tingling in the hands/feet	0.241	0.068	0.190	-0.077
Pain	0.282	0.056	0.267	0.003
Sweats	0.314	0.108	0.159	0.151

<sup>a</sup>Extraction method: unweighted least squares. Rotation method: Geomin (oblique) rotation. Bold fonts indicate factor loading for symptom was >0.40.

Appendix Table 6  
Exploratory Factor Analysis Using Ratings of Symptom Severity Approximately One Week After Chemotherapy Administration (Time 2)<sup>a</sup>

Symptoms	Factor 1	Factor 2	Factor 3	Factor 4
	Psychological Symptom Cluster	Chemotherapy-Related Symptom Cluster	Weight Change Symptom Cluster	Epithelial Symptom Cluster
Cough	-0.081	<b>0.544</b>	0.173	0.001
Dry mouth	-0.160	<b>0.676</b>	0.015	0.072
Nausea	0.037	<b>0.615</b>	-0.049	-0.057
Feeling bloated	0.192	<b>0.443</b>	0.146	0.011
Change in the way food tastes	-0.062	<b>0.538</b>	-0.188	0.320
Abdominal cramps	0.061	<b>0.571</b>	0.041	-0.083
Feeling drowsy	0.208	<b>0.440</b>	-0.016	0.035
Sweats	0.143	<b>0.486</b>	0.208	-0.052
Lack of appetite	0.036	<b>0.669</b>	- <b>0.451</b>	0.088
Weight loss	-0.008	<b>0.481</b>	- <b>0.430</b>	0.118
Numbness/tingling in hands/feet	0.054	<b>0.521</b>	0.022	-0.187
Lack of energy	<b>0.435</b>	<b>0.430</b>	-0.190	-0.018
Difficulty concentrating	<b>0.517</b>	0.217	0.043	0.118
Feeling nervous	<b>0.606</b>	0.115	0.090	0.022
Feeling sad	<b>0.811</b>	-0.004	-0.042	0.072
Worrying	<b>0.940</b>	-0.057	-0.025	-0.011
Feeling irritable	<b>0.562</b>	0.183	-0.033	0.085
Problems with sexual interest or activity	<b>0.402</b>	0.128	0.103	-0.037
Increased appetite	-0.073	0.153	<b>0.708</b>	0.085
Weight gain	0.120	-0.041	<b>0.781</b>	0.068
Itching	0.067	0.132	0.136	<b>0.433</b>
Hair loss	0.082	0.098	0.089	<b>0.450</b>
"I don't look like myself"	0.381	0.029	-0.031	<b>0.459</b>
Changes in the skin	0.217	-0.044	0.017	<b>0.705</b>
Diarrhea	0.010	<b>0.541</b>	-0.124	-0.161
Constipation	0.161	0.336	-0.023	0.020
Dizziness	0.050	0.397	-0.003	0.184
Difficulty sleeping	0.239	0.386	0.100	-0.021
Pain	0.314	0.354	0.086	-0.197

<sup>a</sup>Extraction method: unweighted least squares. Rotation method: Geomin (oblique) rotation. Bold fonts indicate factor loading for symptom was >0.40.

Appendix Table 7  
Exploratory Factor Analysis Using Ratings of Symptom Severity Approximately Two Weeks After Chemotherapy Administration (Time 3)<sup>a</sup>

Symptoms	Factor 1	Factor 2	Factor 3	Factor 4
	Psychological Symptom Cluster	Chemotherapy-Related Symptom Cluster	Weight Change Symptom Cluster	Epithelial Symptom Cluster
Difficulty concentrating	<b>0.453</b>	0.307	0.026	0.029
Feeling nervous	<b>0.773</b>	0.031	0.027	0.017
Feeling sad	<b>0.872</b>	-0.087	-0.028	0.115
Worrying	<b>0.949</b>	-0.038	-0.051	-0.073
Feeling irritable	<b>0.594</b>	0.095	-0.029	0.178
Constipation	<b>0.404</b>	0.121	0.010	0.158
Lack of energy	<b>0.429</b>	<b>0.516</b>	0.025	-0.133
Cough	-0.036	<b>0.428</b>	0.057	0.060
Dry mouth	-0.010	<b>0.518</b>	0.015	0.020
Nausea	0.202	<b>0.518</b>	-0.066	-0.044
Feeling drowsy	0.095	<b>0.626</b>	0.105	-0.054
Numbness/tingling in the hands/feet	0.040	<b>0.416</b>	0.144	-0.014
Diarrhea	-0.035	<b>0.557</b>	-0.156	-0.070
Abdominal cramps	0.259	<b>0.423</b>	-0.126	0.027
Dizziness	0.105	<b>0.425</b>	0.145	0.175
Change in the way food tastes	-0.100	<b>0.440</b>	-0.031	0.347
Lack of appetite	0.036	<b>0.629</b>	-0.442	0.200
Weight loss	-0.054	<b>0.605</b>	-0.411	0.249
Increased appetite	-0.076	0.089	<b>0.621</b>	0.102
Weight gain	0.011	-0.017	<b>1.094</b>	0.051
Itching	-0.039	0.045	0.115	<b>0.483</b>
"I don't look like myself"	0.298	0.024	0.133	<b>0.632</b>
Changes in the skin	0.261	-0.056	-0.028	<b>0.698</b>
Sweats	0.348	0.176	0.196	-0.004
Feeling bloated	0.369	0.253	0.045	-0.061
Problems with sexual interest or activity	0.363	0.129	-0.019	0.071
Hair loss	0.147	0.153	0.018	0.333
Difficulty sleeping	0.314	0.341	0.123	0.054
Pain	0.314	0.280	0.103	-0.103

<sup>a</sup>Extraction method: unweighted least squares. Rotation method: Geomin (oblique) rotation. Bold fonts indicate factor loading for symptom was >0.40.

*Appendix Table 8*  
**Exploratory Factor Analysis Using Ratings of Symptom Distress Before the Initiation of Next Dose of Chemotherapy (Time 1)<sup>a</sup>**

Symptoms	Factor 1	Factor 2	Factor 3	Factor 4
	Psychological Symptom Cluster	Chemotherapy-Related Symptom Cluster	Weight Change Symptom Cluster	Gastrointestinal Symptom Cluster
Difficulty concentrating	<b>0.767</b>	-0.030	-0.083	0.037
Feeling nervous	<b>0.707</b>	-0.060	0.047	0.001
Feeling sad	<b>0.760</b>	0.041	0.084	-0.137
Worrying	<b>0.959</b>	-0.166	0.040	-0.102
Feeling irritable	<b>0.618</b>	0.071	-0.013	0.119
Lack of energy	<b>0.552</b>	0.252	-0.235	0.051
Feeling drowsy	<b>0.488</b>	0.240	-0.099	0.079
Difficulty sleeping	<b>0.407</b>	0.140	0.030	0.095
Pain	<b>0.459</b>	0.109	0.002	0.117
Sweats	<b>0.502</b>	0.031	0.093	0.075
Dizziness	0.093	<b>0.564</b>	0.031	0.022
Change in the way food tastes	0.046	<b>0.559</b>	0.058	0.052
Lack of appetite	-0.041	<b>0.807</b>	-0.246	-0.030
Weight loss	-0.010	<b>0.602</b>	-0.233	0.048
Itching	-0.089	<b>0.516</b>	0.263	0.024
"I don't look like myself"	0.187	<b>0.537</b>	0.059	-0.207
Changes in the skin	0.268	<b>0.622</b>	0.034	-0.293
Hair loss	0.020	<b>0.449</b>	0.118	0.100
Increased appetite	-0.004	0.050	<b>0.779</b>	0.241
Weight gain	0.050	-0.018	<b>0.929</b>	0.001
Diarrhea	0.064	0.063	0.087	<b>0.620</b>
Abdominal cramps	0.289	-0.029	0.024	<b>0.621</b>
Constipation	0.297	0.279	-0.135	0.089
Cough	0.066	0.322	0.075	0.028
Dry mouth	0.081	0.344	0.113	0.205
Nausea	0.252	0.367	-0.133	0.262
Numbness/tingling in the hands/feet	0.321	0.150	-0.046	0.156
Feeling bloated	0.356	0.103	0.126	0.358
Problems with sexual interest or activity	0.384	0.278	-0.016	-0.170

<sup>a</sup>Extraction method: unweighted least squares. Rotation method: Geomin (oblique) rotation. Bold fonts indicate factor loading for symptom was >0.40.

Appendix Table 9  
Exploratory Factor Analysis Using Ratings of Symptom Distress Approximately One Week After Chemotherapy Administration (Time 2)<sup>a</sup>

Symptoms	Factor 1	Factor 2	Factor 3	Factor 4
	Psychological Symptom Cluster	Chemotherapy-Related Symptom Cluster	Weight Change Symptom Cluster	Epithelial Symptom Cluster
Cough	-0.122	<b>0.571</b>	0.200	0.005
Dry mouth	-0.057	<b>0.629</b>	0.065	0.003
Nausea	0.061	<b>0.564</b>	-0.012	0.018
Feeling drowsy	0.286	<b>0.423</b>	-0.012	0.031
Diarrhea	0.107	<b>0.474</b>	-0.074	-0.123
Abdominal cramps	0.066	<b>0.570</b>	0.104	-0.021
Change in the way food tastes	-0.062	<b>0.552</b>	-0.208	0.351
Lack of appetite	0.015	<b>0.714</b>	-0.395	0.098
Weight loss	0.041	<b>0.536</b>	-0.324	0.021
Sweats	0.255	<b>0.403</b>	0.256	-0.047
Lack of energy	<b>0.514</b>	0.339	-0.121	0.014
Difficulty concentrating	<b>0.527</b>	0.141	-0.050	0.155
Feeling nervous	<b>0.751</b>	0.019	0.017	-0.015
Feeling sad	<b>0.784</b>	-0.025	0.010	0.075
Worrying	<b>0.992</b>	-0.193	-0.005	0.035
Feeling irritable	<b>0.630</b>	0.105	-0.042	0.077
Difficulty sleeping	<b>0.404</b>	0.260	0.099	-0.054
Problems with sexual interest or activity	<b>0.467</b>	0.010	0.147	0.015
Increased appetite	0.038	0.081	<b>0.726</b>	0.085
Weight gain	-0.021	-0.037	<b>0.877</b>	0.207
Itching	0.025	0.104	0.117	<b>0.469</b>
"I don't look like myself"	0.236	0.061	0.034	<b>0.511</b>
Changes in the skin	0.089	-0.064	-0.020	<b>0.820</b>
Hair loss	0.094	0.067	0.067	<b>0.489</b>
Constipation	0.147	0.309	0.071	0.095
Numbness and/or tingling in the hands and/or feet	0.210	0.376	-0.008	-0.112
Dizziness	0.082	0.345	0.011	0.196
Feeling bloated	0.231	0.390	0.199	0.031
Pain	0.384	0.266	0.167	-0.098

<sup>a</sup>Extraction method: unweighted least squares. Rotation method: Geomin (oblique) rotation. Bold fonts indicate factor loading for symptom was >0.40.

Appendix Table 10  
Exploratory Factor Analysis Using Ratings of Symptom Distress Approximately Two Weeks After Chemotherapy Administration (Time 3)<sup>a</sup>

Symptoms	Factor 1	Factor 2	Factor 3	Factor 4
	Psychological Symptom Cluster	Chemotherapy-Related Symptom Cluster	Weight Change Symptom Cluster	Epithelial Symptom Cluster
Lack of energy	<b>0.524</b>	0.378	-0.021	0.013
Difficulty concentrating	<b>0.485</b>	0.232	0.054	0.102
Feeling nervous	<b>0.729</b>	0.060	0.045	-0.136
Feeling sad	<b>0.969</b>	-0.188	-0.024	0.071
Worrying	<b>0.959</b>	-0.059	0.014	-0.157
Feeling irritable	<b>0.642</b>	0.117	-0.081	0.077
Constipation	<b>0.422</b>	0.150	-0.001	0.150
Cough	-0.055	<b>0.528</b>	0.037	-0.049
Dry mouth	0.025	<b>0.506</b>	0.046	-0.027
Nausea	0.253	<b>0.479</b>	-0.040	-0.038
Feeling drowsy	0.202	<b>0.520</b>	0.050	0.028
Diarrhea	0.072	<b>0.462</b>	-0.103	-0.089
Abdominal cramps	0.233	<b>0.462</b>	-0.129	-0.093
Change in the way food tastes	-0.021	<b>0.482</b>	-0.039	0.275
Lack of appetite	0.026	<b>0.705</b>	<b>-0.467</b>	0.044
Weight loss	-0.077	<b>0.645</b>	<b>-0.446</b>	0.092
Increased appetite	-0.092	0.099	<b>0.652</b>	0.334
Weight gain	0.026	-0.041	<b>0.965</b>	0.348
Itching	0.002	0.026	0.023	<b>0.526</b>
"I don't look like myself"	0.394	0.047	0.034	<b>0.584</b>
Changes in the skin	<b>0.432</b>	-0.041	-0.128	<b>0.624</b>
Difficulty sleeping	0.336	0.314	0.137	0.101
Problems with sexual interest or activity	<b>0.418</b>	0.071	-0.142	0.060
Sweats	0.331	0.205	0.271	-0.026
Hair loss	0.258	0.187	0.012	0.300
Numbness/tingling in the hands/feet	0.212	0.378	0.176	-0.079
Dizziness	0.179	0.363	0.116	0.226
Feeling bloated	0.378	0.233	0.129	-0.060
Pain	0.381	0.265	0.048	-0.085

<sup>a</sup>Extraction method: unweighted least squares. Rotation method: Geomin (oblique) rotation. Bold fonts indicate factor loading for symptom was >0.40.